Academic Journal
Q1Lara D. Veeken
About Lara D. Veeken
Lara D. Veeken is a scholarly journal published by Oxford University Press. SCImago 2025 places it in Q1 with an SJR of 1.751 and an H-index of 212.
Its listed coverage is 1952-1995, 1998-2026 and its research categories include Pharmacology (medical) (Q1); Rheumatology (Q1). The 2025 dataset reports 969 documents and 7702 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, Systemic Sclerosis and Related Diseases, Autoimmune and Inflammatory Disorders Research, Musculoskeletal Disorders and Rehabilitation.
Recent Research Articles
Latest publications matched automatically by ISSN.
The BAFF–BAFF-R axis in systemic sclerosis: a reciprocal signature of active B-cell dysregulation
Takashi Matsushita
2026-09-04 · DOI: 10.1093/rheumatology/keag477Inflammaging reshapes the immune ecosystem in IgG4-related dacryoadenitis and sialadenitis
Motohisa Yamamoto, Ryuta Kamekura, Masaaki Uehara, Yuta Ichii et al.
2026-09-04 · DOI: 10.1093/rheumatology/keag480Comment on: Gastrointestinal involvement in dermatomyositis: multicentric retrospective cohort study
Hamit Küçük, İbrahim Yahya Çakır, Berna Göker
2026-09-03 · DOI: 10.1093/rheumatology/keag469Patterns and changes in lifestyle habits of patients with rheumatoid arthritis during the first three years post-diagnosis
Marie-Louise Karlsson, Simon Steiger, Helga Westerlind, Lars Klareskog et al.
2026-08-31 · DOI: 10.1093/rheumatology/keag472Self-efficacy in idiopathic inflammatory myopathies: associated factors, profiles, and patient-reported outcomes
Praggya Yaadav, Lekshmi M Rahulan, Suhana Hussain, Manali Sarkar et al.
2026-08-25 · DOI: 10.1093/rheumatology/keag458Real-world experience with obinutuzumab in difficult-to-treat myositis: concise report of a case series
Ivana Ilic, Sonali Narain, Galina Marder
2026-08-25 · DOI: 10.1093/rheumatology/keag435Describing flares: A mixed methods study comparing patient and clinician perspectives in systemic lupus erythematosus and other rheumatic diseases
Martha A Piper, Alice Tunks, James A Bourgeois, Lucy Calderwood et al.
2026-08-20 · DOI: 10.1093/rheumatology/keag443Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial
Pauline M E T Bovens, Céleste J T van der Togt, Nathan den Broeder, Lise M Verhoef et al.
2026-08-18 · DOI: 10.1093/rheumatology/keag420Comment on: Acute myocarditis after switching between two adalimumab biosimilars: reply
Thomas Subervie, François Sauer, Marc Scherlinger
2026-08-18 · DOI: 10.1093/rheumatology/keag439Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the Phase 3 BE MOBILE rials
Martin Rudwaleit, Sofia Ramiro, Denis Poddubnyy, Marina Magrey et al.
2026-08-14 · DOI: 10.1093/rheumatology/keag425How do individual monosodium urate depositions respond to urate-lowering therapy? A systematic evaluation using the dual-energy CT modality
Sara Nysom Christiansen, Mikkel Østergaard, Lene Terslev, Ole Slot et al.
2026-09-01 · DOI: 10.1093/rheumatology/keag393Attainment of early targets does not ensure a complete response at 12 months in lupus nephritis, especially in nephrotic-range proteinuria
Maria Pappa, Konstantinos Drougkas, Antigone Pieta, Maria Kosmetatou et al.
2026-08-01 · DOI: 10.1093/rheumatology/keag411Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study
Rachel Charlton, William Tillett, Neil McHugh, Anita McGrogan et al.
2026-08-01 · DOI: 10.1093/rheumatology/keag395Correction to: Genetic landscape of early-onset systemic lupus erythematous in India
2026-08-01 · DOI: 10.1093/rheumatology/keag357Correction to: Serial assessment of ultrasound sensitivity and scores in patients with giant cell arteritis before and 3 and 10 days after treatment
2026-08-01 · DOI: 10.1093/rheumatology/keag397Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease
Kanako Shimanuki, Mitsuhiro Akiyama, Koichi Saito, Waleed Alshehri et al.
2026-08-01 · DOI: 10.1093/rheumatology/keag417When a positive ANA truly matters: evidence from a Danish national cohort
Kenji Oku
2026-08-01 · DOI: 10.1093/rheumatology/keag418A simple heart failure detection score for rheumatology practice: findings from the KURAMA cohort
Kosaku Murakami, Hideaki Inazumi, Akira Onishi, Shuichiro Nakabo et al.
2026-08-01 · DOI: 10.1093/rheumatology/keag403Mortality and early complications in systemic lupus erythematosus: an unbroken pattern of ethnic inequality
Sofia Ajeganova
2026-08-01 · DOI: 10.1093/rheumatology/keag404Does obesity change the meaning of treatment targets in psoriatic arthritis?
Giuseppe Lopalco, Florenzo Iannone, Vincenzo Venerito
2026-08-01 · DOI: 10.1093/rheumatology/keag408Reviews
Community Reviews
Version History
September 8, 2026 at 12:04 am
September 8, 2026